The team behind LVT-NEXUS
Lovaltech brings together the scientists behind the technology, pharmaceutical development specialists (CMC, quality, regulatory affairs) and leaders from the pharma industry. Together, we are taking LVT-NEXUS, our mucosal delivery platform, from research to the clinic.
FOUNDERS
Patrick Barillot has spent his entire career in the pharmaceutical industry, in export, sales leadership and business unit management at Virbac, Boehringer Ingelheim, Wyeth (Pfizer) and Recipharm. An ESSEC graduate in international general management, he left Recipharm in December 2021 to found Lovaltech and has been its President since January 2022.
Isabelle Dimier-Poisson is Professor at the University of Tours and Director of the BioMAP team (UMR ISP 1282, University of Tours–INRAE). An expert in vaccinology and mucosal immunity, she initiated the project and co-founded Lovaltech in January 2022. She advises the company on its scientific strategy, the LVT-NEXUS platform and the development of LVT-001. Her projects have led to four patent families, all taken forward through new companies (VitamFero, Vaxinano, Kymeris) or industrial partnerships. A laureat of the national France Vaccin programme, she helps define and develop next-generation vaccines.
Mathieu Epardaud is an immunologist specialising in immunotherapy and vaccinology. He joined the BioMAP team (University of Tours - INRAE) in 2018 to contribute to the development of mucosal vaccine platforms, after working on a range of immunology topics at the Dana-Farber Cancer Institute (Harvard Medical School, Boston) and at INRA (Jouy-en-Josas). A co-founder of Lovaltech, he leads the transfert of the technology from lab to clinic: translational development, relations with industry, and association between LVT-NEXUS and its nasal spray medical device. He also coordinates mucosal vaccination research at the University of Tours, which contribute to Lovaltech’s pipeline extension.
Nicolas Aubrey is an Associate Professor of Biochemistry at the Faculty of Pharmacy of the University of Tours and an associate researcher at BioMAP (University of Tours - INRAE). An expert in complex recombinant protein engineering, he has authored 32 international publications and is an inventor on 5 patent families, including as lead inventor of the patent covering LVT-001’s antigenic protein. His recombinant protein production platform has led to numerous collaborations with pharmaceutical companies. A co-founder of Lovaltech, he contributes to the development of the next vaccine candidates.
MANAGEMENT
Mélanie Rose holds a PhD in immuno-oncology. She has coordinated R&D, regulatory and clinical teams and built academic and industrial partnerships in biotech companies. As Chief Innovation Officer at Lovaltech since 2026, she shapes the pipeline of the LVT-NEXUS mucosal delivery platform, contributes to intellectual property management and helps structure the company.
Alan Mougeolle is a biotech engineer who contributed to the launch of two first-in-class Phase I/II clinical trials at a polyclonal antibody biotech, first as a production engineer and then as CMC manager. Drawing on this experience of taking companies through the first stages of clinical development, he joined Lovaltech in 2024 as Head of CMC. He is building the company’s quality control, document management and product data consolidation, and supports the team on regulatory affairs.
Julie Canovas is a biotech engineer with more than 18 years’ experience in biotechnology and pharmaceutical manufacturing. She began her career at GSK Vaccines, where she led technology transfer projects for products with marketing authorisation. After a period in operational quality consulting and a role as Industrialisation Manager in cell therapy, she joined Lovaltech in 2025 as Quality Manager. She is structuring document management and product data consolidation, and provides key support to CMC operations and regulatory activities.
Muna Aljieli is an Assistant Professor of Clinical Pharmacy with a PhD in immunotherapy and more than nine years’ academic experience. She was postdoctoral researcher in the BioMAP team, where she built expertise in mucosal immunity. She joined Lovaltech in January 2025 to coordinate research activity.
Rodolphe Carpentier is a research engineer in biology specialising in vaccine development based on nanomedicine approaches. With over 15 years of academic research, 27 publications and an h-index of 20 (September 2025), he has deep expertise in the pharmaceutical formulation of nanoparticle carriers, mucosal biology and toxicological assessment. He is a key contributor to strengthening and structuring the development of LVT-ME, the proprietary muco-excipient at the core of LVT-NEXUS.